CLINICAL AND PATHOGENETIC ASPECTS OF ISCHAEMIC HEART DISEASE COMPLICATED BY CHTONIC HEART FAILURE
N P Dorofeeva , S A Pleskachev , S V Shlyk , E V Tchigaeva , E A TherAnanyanz , O G Mashtalova , I E Koulikova , A S Pleskachev , S S Todorov
Journal of Clinical Practice ›› 2011, Vol. 2 ›› Issue (1) : 67 -73.
CLINICAL AND PATHOGENETIC ASPECTS OF ISCHAEMIC HEART DISEASE COMPLICATED BY CHTONIC HEART FAILURE
Objectives: To investigate genetic and neurohumoral determinants of chronic heart failure (CHF) development and progression in ischaemic heart disease (IHD) patients. Methods: Serum neurohormone level analysis (angiotensin II, aldosterone, endotheline1, NTproBNP, TNFα) and genotyping (genes encoding ACE, angiotensinogen, and type1 angiotensin II receptors ) were implemented in 100 patients Results: Activation of endotheline and NTproBNP is characteristic of early CHF stages while decompensation of chronic heart failure shows elevation in aldosterone and TNFα . Structural polymorphism of renineangiotensine system genes is not significant in CHF development and progression in IHD patients.
neurohormones / genetic polymorphism / reninangeotensin system / chronic heart failure
| [1] |
Агеев Ф.Т., Даниелян М.О., Мареев В.Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХАОХСН) // Журнал сердечная недостаточность. 2004. Т. 5 (1). С. 47. |
| [2] |
Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis // Eur. Heart J. 2003. Vol. 24 (5). P. 442-463. |
| [3] |
Ho K.K., Pinsky J.L., Kannel W.B. et al. The epidemiology of heart failure: Fremigham Study // J. Am. Coll. Cardiol. 1993. Vol. 22 (suppl. A). P. 6A-13A. |
| [4] |
Bay M., Kirk V., Parner J. et al. NTproBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular sys tolic function // Heart. 2003. Vol. 89 (2). P. 150-154. |
| [5] |
Fatini C., Abbate R., Pepe G. et al. Searching for a better assessment of the individual coronary risk profile: the role of angiotensinconverting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms // Eur. Heart J. 2000. Vol. 21 (8). P. 633-638. |
| [6] |
Fuat A., Murphy J.J., Hungin A.P. et al. The diagnostic accuracy and utility of a Btype natriuretic peptide test in a community population of patients with suspected heart failure // Br. J. Gen. Pract. 2006. Vol. 56 (526). P. 327-333. |
| [7] |
Pfohl M., Koch M., Prescod S. et al. Angiotensin Iconverting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study // Eur. Heart J. 1999. Vol. 20 (18). P. 1318-1325. |
| [8] |
Katz A. Maladaptive hypertrophy and the cardiomyoparty of overload: Familial cardiomyopathies / In: Katz A. (ed.): Heart failure: Pathophysiology, molecular biology and clinical management. Philadelphia, Lippincott Williams Wilkins. 2000. P. 277-308. |
| [9] |
Latini R., Masson S., Anand I. еt al. The comparative prognostic value of plasma neurehormones at baseline in patients with heart failure enrolled in ValHeFT // Eur. Heart J. 2004. Vol. 25 (4). P. 292-299. |
| [10] |
Serneri G.G., Boddi M., Cecioni I. et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function // Circ. Res. 2001. Vol. 88 (9). P. 961-968. |
| [11] |
Zaman A.G., Helft G., Worthley S.G., Badimon J.J. The Role of plaque rupture and thrombosis in coronary artery disease // Atherosclerosis. 2000. Vol. 149 (2). P. 251-256. |
| [12] |
Groenning B.A., Nilsson J.C., Sondergaard L. et al. Detection of left ventricular enlargement and impaired systolic function with plasma Nterminal pro brain natriuretic peptide concentrations // Am. Heart J. 2002. Vol. 143 (5). P. 23-29. |
| [13] |
Maisel A.S., Koon J., Krishnaswamy P. et al. Utility of Bnatriuretic peptide as a rapid, pointofcare test for screening patients undergoing echocardiography to determine left ventricular dysfunction // Am. Heart J. 2001. Vol. 141 (3). P. 367-374. |
| [14] |
McDonagh T.A., Cunningham A.D., Morrison C.E. et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population // Heart. 2001. Vol. 86 (l). P. 21-26. |
| [15] |
Gardner R.S., Ozalp F., Murday A.J. et al. Nterminal probrain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure // Eur. Heart J. 2003. Vol. 24 (19). P. 1735-1743. |
| [16] |
Gustafsson F., Badskj J., Hansen F.S. et al. Value of Nterminal proBNP in the diagnosis of left ventricular systolic dysfunction in primary care patients referred for echocardiography // Heart Drug. 2003. Vol. 3. P. 141-146. |
| [17] |
Feldman A.M., Combes A., Wagner D. et al. The role of tumor necrosis factor in the pathophysiology of heart failure // Am. Col. Cardiol. 2000. Vol. 35 (3). P. 537-544. |
| [18] |
Терещенко С.Н., Джаиани Н.А., Моисеев В.С. Генетические аспекты хронической сердечной недостаточности // Тер. арх. 2000. Т. 72 (4). С. 75-77. |
| [19] |
Шляхто Е.В., Конради А.О. Блокирование ренинангиотензиновой системы при артериальной гипертензии: фармакогенетический подход // Артериальная гипертензия. 2002. Т. 4 (3). С. 24-27. |
Dorofeeva N.P., Pleskachev S.A., Shlyk S.V., Tchigaeva E.V., TherAnanyanz E.A., Mashtalova O.G., Koulikova I.E., Pleskachev A.S., Todorov S.S.
/
| 〈 |
|
〉 |